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patients with stage IIIC endometrial cancer, we found significant efficacy of the sandwich regimen compared with
the sequential strategy for the overall survival of patients
with stage IIIC EC (hazard ratio, 1.89; 95% confidence
interval, 1.04-3.45; P = .04), with borderline significance
for progression-free survival (hazard ratio, 1.57; 95% confidence interval, 0.92-2.69; P = .09), contrary to what was
mentioned in the article.
Previous research has found that the sandwich regimen was feasible and well tolerated, although it was
associated with more hematologic toxicity and treatment
breaks than upfront ChT followed by RT.5,6 Given the
lack of difference in treatment outcomes between adjuvant therapy regimens, toxicity becomes more significant
in this situation.
To summarize, this is an interesting study that examines
the sequence and type of adjuvant treatment modalities
used in patients with stage IIIC EC. Clarification of the
aforementioned points will aid in a more complete understanding of the current study’s findings.
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In Reply to Onal et al.

To the Editor: The majority of patients in our study
received external beam radiation (EBRT) with or without
brachytherapy (BT) (n = 592; 86%), whereas a small proportion of patients were treated with chemotherapy and BT
(chemo-brachy) (n = 94; 14%). A subgroup analysis was performed excluding patients treated with chemo-brachy and
upfront radiation therapy. No differences in outcomes were
found for overall survival (OS) and disease-free survival for
the main 3 sequencing approaches (upfront chemotherapy,
concurrent and sandwich).1 Although patients treated with
chemo-brachy had similar clinical outcomes compared with
the other sequencing regimens, the rate of paraortic lymph
node § pelvic recurrence was significantly higher in patients
treated with chemo-brachy (15% vs 5%).
Several studies have evaluated the role of BT in combination with chemotherapy in patients with stage III endometrial cancer (EC). A retrospective study including 83
patients with stage III EC treated with adjuvant chemotherapy and BT reported excellent local control rates.2 In a
National Cancer Database study, patients treated with chemotherapy and EBRT had similar survival outcomes compared with chemotherapy and BT, even when categorizing
patients as low or high risk according to age, grade, and
stage.3 Given the controversial role of BT in combination
with chemotherapy in patients with stage III EC, we
included these patients in our study to highlight the importance of EBRT in reducing pelvic and paraortic lymph node
recurrences.
As for the doses of EBRT, the median dose delivered was
45 Gy. The range reported in the manuscript was determined
by the minimum and maximum values of doses. The interquartile range was 45 to 56 Gy. A total of 6 patients received doses
inferior to 45 Gy, but they were not excluded from the study
because the impact would be minimal on clinical outcomes.
We acknowledge the incorrectly interpreted study by
Onal et al and thank the authors for clarifying their results.4
Although OS was significantly higher in the sandwich arm,
disease-free survival was not affected by treatment
sequence.5 Indeed, other prognostic factors could affect
OS, such as the age-adjusted Charlson comorbidity index,
which was found to be an independent prognostic factor for
OS independent of treatment received.6 Evaluating OS in
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this population may not reflect the true impact of other very
important prognostic factors.
The goal of our study was to reflect clinical practices
across the United States and Canada and report real-world
experience in managing stage IIIC EC.
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